Symptomatic Relief of Skin Toxicities Induced by EGFR TKI Therapy: Use of Bicarbonate Ion Bath Salts

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for non–small cell lung cancer with EGFR gene mutation is associated with a high occurrence of skin disorders, such as dermatitis, dry skin, and paronychia. Moisturizers, steroids, and oral minocycline are used to treat these adverse effects, with limited efficacy. We conducted a pilot study to investigate the usefulness of bicarbonate ion bath salts, which are known to have excellent moisturizing properties, for treating skin disorders caused by EGFR TKI therapy.